CMRX
Chimerix, Inc.
stock NASDAQ

Lexicon Pharmaceuticals (LXRX) has a strong potential to go past $3 based on several factors:
-: The average among 7 analysts is $3.23, representing a large upside from the current price of $1.34.
- *Analyst Ratings*: LXRX has received 3 buy ratings, 3 hold ratings, and 1 sell rating, indicating a generally positive outlook.
- *Forecasted Upside*: Analysts predict a potential upside of 140.67% in the next 12 months.
- *Recent Developments*: Positive data from the company's Phase 2b study of LX9211 for neuropathic pain and progress in its pipeline could contribute to the stock's growth.
- *Market Sentiment*: Short interest in LXRX has decreased by 1.72%, indicating improving investor sentiment.
- *Growth Potential*: The company's revenue growth is expected to increase by 66.55% this year, and earnings are expected to improve from ($0.66) to ($0.45) per share in the coming year
Lexicon Pharmaceuticals (LXRX) could be the next (CMRX) based on several factors:
- *Similar Market Capitalization*: CMRX's market cap was around $400-$500 million before its recent surge. LXRX currently has a market cap of approximately $481.50-$486.95 million, making it a potential candidate for similar growth.
- *Biotech Catalysts*: Both companies have promising biotech pipelines with potential catalysts. LXRX has LX9211 for neuropathic pain and sotagliflozin for heart failure and diabetes, while CMRX had promising treatments in its pipeline.
- *Recent Partnerships and Collaborations*: LXRX has partnered with Novo Nordisk for LX9851 and has ongoing discussions for pilavapadin, demonstrating potential interest from larger pharmaceutical companies.
- *Upcoming Earnings and Data Readouts*: LXRX is set to report Q3 2025 earnings on November 6, 2025, and has several upcoming data readouts and medical meetings, which could provide catalysts for stock growth.
- *Analyst Sentiment*: LXRX has a "Buy" rating from analysts with a consensus price target of $3.23, representing a potential upside of 141.05%.
Given these similarities and potential catalysts, investors might view LXRX as a stock with growth potential similar to CMRX. However, it's essential to conduct thorough research and consider multiple factors before making investment decisions. Key statistics to consider include:
- *Current Price*: $1.34
- *52-Week Range*: $0.28-$2.08
- *Market Cap*: $481.50-$486.95 million
- *Analyst Price Target*: $3.23 (+141.05% upside)
Yes this was written by AI and posted by a human retail investor. Positions: over 30k shares at prices between 0.5 and 1.34. Do your own DD, but it's gotta be better than other low volume pumps this week 🙄 Long play, not in it for the squeeze

Lexicon Pharmaceuticals (LXRX) has a strong potential to go past $3 based on several factors:
-: The average among 7 analysts is $3.23, representing a large upside from the current price of $1.34.
- *Analyst Ratings*: LXRX has received 3 buy ratings, 3 hold ratings, and 1 sell rating, indicating a generally positive outlook.
- *Forecasted Upside*: Analysts predict a potential upside of 140.67% in the next 12 months.
- *Recent Developments*: Positive data from the company's Phase 2b study of LX9211 for neuropathic pain and progress in its pipeline could contribute to the stock's growth.
- *Market Sentiment*: Short interest in LXRX has decreased by 1.72%, indicating improving investor sentiment.
- *Growth Potential*: The company's revenue growth is expected to increase by 66.55% this year, and earnings are expected to improve from ($0.66) to ($0.45) per share in the coming year
Lexicon Pharmaceuticals (LXRX) could be the next (CMRX) based on several factors:
- *Similar Market Capitalization*: CMRX's market cap was around $400-$500 million before its recent surge. LXRX currently has a market cap of approximately $481.50-$486.95 million, making it a potential candidate for similar growth.
- *Biotech Catalysts*: Both companies have promising biotech pipelines with potential catalysts. LXRX has LX9211 for neuropathic pain and sotagliflozin for heart failure and diabetes, while CMRX had promising treatments in its pipeline.
- *Recent Partnerships and Collaborations*: LXRX has partnered with Novo Nordisk for LX9851 and has ongoing discussions for pilavapadin, demonstrating potential interest from larger pharmaceutical companies.
- *Upcoming Earnings and Data Readouts*: LXRX is set to report Q3 2025 earnings on November 6, 2025, and has several upcoming data readouts and medical meetings, which could provide catalysts for stock growth.
- *Analyst Sentiment*: LXRX has a "Buy" rating from analysts with a consensus price target of $3.23, representing a potential upside of 141.05%.
Given these similarities and potential catalysts, investors might view LXRX as a stock with growth potential similar to CMRX. However, it's essential to conduct thorough research and consider multiple factors before making investment decisions. Key statistics to consider include:
- *Current Price*: $1.34
- *52-Week Range*: $0.28-$2.08
- *Market Cap*: $481.50-$486.95 million
- *Analyst Price Target*: $3.23 (+141.05% upside)
Yes this was written by AI and posted by a human retail investor. Positions: over 30k shares at prices between 0.5 and 1.34. Do your own DD, but it's gotta be better than other low volume pumps this week 🙄 Long play, not in it for the squeeze